Vascular endothelial growth factor 2
AssigneeHuman Genome Sciences, Inc.
InventorsCraig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
Life of this patent
Estimating the term…
Abstract
Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
Claims13
A method of treating or ameliorating an inflammatory disease or disorder mediated by human VEGF-2 in a human subject comprising administering to the subject an isolated antibody or antigen binding fragment thereof that specifically binds to a human VEGF-2 polypeptide in an amount effective to treat or ameliorate to the inflammatory disease or disorder in the subject, wherein the isolated antibody or antigen binding fragment thereof inhibits binding of human VEGF-2 to flk-1 or Flt-4 and wherein the isolated antibody or antigen binding fragment thereof comprises:
- (a) an amino acid sequence that is at least 96% identical to the amino acid sequence of the VH domain of the antibody expressed by the hybridoma cell line deposited under ATCC Deposit No. PTA-4095, with the proviso that the amino acid sequence of the isolated antibody or antigen binding fragment thereof includes the amino acid sequences of the VHCDR1, VHCDR2, and VHCDR3 regions of the antibody expressed by the hybridoma deposited under ATCC Deposit No. PTA-4095, and
- an amino acid sequence that is at least 96% identical to the amino acid sequence of the VL domain of the antibody expressed by the hybridoma cell line deposited under ATCC Deposit No. PTA-4095, with the proviso that the amino acid sequence of the isolated antibody or antigen binding fragment thereof includes the amino acid sequences of the VLCDR1, VLCDR2, and VLCDR3 regions of the antibody expressed by the hybridoma deposited under ATCC Deposit No. PTA-4095;
- or
- (b) an amino acid sequence that is at least 96% identical to the amino acid sequence of the VH domain of SEQ ID NO:
- 79, with the proviso that the amino acid sequence of the isolated antibody or antigen binding fragment thereof includes a VHCDR1consisting of the amino acid sequence of amino acid residues 26-35 of SEQ ID NO:
- 79;
- a VHCDR2 consisting of the amino acid sequence of amino acid residues 50-66 of SEQ ID NO:
- 79;
- and a VHCDR3 consisting of the amino acid sequence of amino acid residues 99-107 of SEQ ID NO:
- 79;
- and
- an amino acid sequence that is at least 96% identical to the amino acid sequence of the VL domain of SEQ ID NO:
- 79, with the proviso that the amino acid sequence of the isolated antibody or antigen binding fragment thereof includes a VLCDR1 consisting of the amino acid sequence of amino acid residues 158-170 of SEQ ID NO:
- 79;
- a VLCDR2 consisting of the amino acid sequence of amino acid residues 186-192 of SEQ ID NO:
- 79;
- and a VLCDR3 consisting of the amino acid sequence of amino acid residues 225-236 of SEQ ID NO:
- 79.
Dependencies are inferred from the claim text.